INDIANAPOLIS, Sept. 24, 2021 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) is voluntarily recalling lot D239382D, Expiration April 2022, of Glucagon Emergency Kit for Low Blood Sugar (Glucagon for ...
The US Food and Drug Administration (FDA) has approved a prefilled glucagon rescue pen (Gvoke HypoPen, Xeris Pharmaceuticals) for the treatment of severe hypoglycemia in adult and pediatric patients ...
Please provide your email address to receive an email when new articles are posted on . Fewer people with diabetes filled glucagon prescriptions in 2021 compared with 2011, though increases were seen ...
The Food and Drug Administration (FDA) has approved Gvoke (glucagon; Xeris Pharmaceuticals) for the treatment of severe hypoglycemia in pediatric and adult patients with diabetes aged 2 years and ...
Glucagon is a pancreatic hormone that plays a crucial role in regulating glucose and whole-body energy metabolism. In individuals with diabetes, the pancreatic alpha cells that produce glucagon are ...
The use of glucose tablets to treat hypoglycemia during and after exercise was less with RTU glucagon when compared to standard of care. Treatment-emergent adverse events with a mini dose of RTU ...
CHICAGO--(BUSINESS WIRE)--Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a specialty pharmaceutical company leveraging its novel technology platforms to develop and commercialize ready-to-use injectable ...
Please provide your email address to receive an email when new articles are posted on . “The advent of self-administered low-dose glucagon will change the treatment of hypoglycemia significantly,” ...
If approved, it would be the first room temperature stable liquid glucagon in an autoinjector formulation. Xeris Pharmaceuticals, Inc. announced positive results from a phase 3 trial of its ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results